Product InformationMolecular Weight: 718.79
Solubility: DMSO up to 50 mM
Chemical Name: 3-[(23S,24R)-14-Ethenyl-5-(3-methoxy-3-oxopropyl)-22,23-bis(methoxycarbonyl)-4,10,15,24-tetramethyl-25,26,27,28-tetraazahexacyclo[184.108.40.206,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic acid
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.
Verteporfin (Visudyne) is a potent and selective YAP inhibitor, disrupts YAP-TEAD interactions and enhances trypsin cleavage of YAP with EC50 ~100 nM. It inhibits growth and proliferation of retinoblastoma cells. It also significantly blocks cancer stem cell (CSC) properties in cells with high YAP1 and a high proportion of ALDH1(+). In vivo it can suppress YAP-induced liver overgrowth in mice.
How to Use:
In vitro: Verteporfin was used at 10 µM final concentration in various in vitro assays.
In vivo: Verteporfin was administered by intraperitoneal injection at 100 mg/Kg once every other day in liver overgrowth model.
- 1. Liu-Chittenden Y, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. (2012) Genes Dev. 26(12):1300-5.
- 2. Brodowska K, et al. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. (2014) Exp Eye Res. 124:67-73.
- 3. Song S, et al. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. (2014) Cancer Res. 74(15):4170-82.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.